South Blood Disorder Insight
Published: 16 June 2026 | Report Format: Electronic (PDF)
The South Korea blood disorder market is expected to grow at a rate of 7.3% owing to increasing prevalence of anemia, hemophilia, leukemia, and thalassemia, rising adoption of advanced diagnostics, expanding healthcare infrastructure, and growing investments in hematology research.
South Korea Blood Disorder Market Insights Forecasts to 2035
- The South Korea Blood Disorder Market Size Was Estimated at USD 1.28 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.3% from 2025 to 2035
- The South Korea Blood Disorder Market Size is Expected to Rise Around USD 2.59 Billion by 2035
Notable Insights for the South Korea Blood Disorder Market
- The disease-based segmentation indicates that Anemia, Hematologic Malignancies & Hemophilia segment holds a commanding position with nearly 58% market share in the South Korea Blood Disorder Market in 2025 due to increasing diagnosis rates and growing treatment accessibility.
- The treatment-based segmentation shows that Pharmaceuticals, Biologics & Blood Transfusion Services segment dominates with approximately 63% market share in the South Korea Blood Disorder Market in 2025 owing to rising demand for targeted therapies and supportive care solutions.
- The global revenue of Roche Holding AG in fiscal year 2025 was supported by increasing demand for hematology therapies, oncology treatments, diagnostic technologies, and precision medicine solutions across global healthcare markets.
- Rising investments in gene therapies, precision diagnostics, and advanced hematology research programs are expected to accelerate market growth, while innovative blood disorder treatment technologies improve diagnostic accuracy by nearly 41% and enhance treatment outcomes by approximately 33%.
Download the eBook (ToC)
Research Methodologies Used to Analyze the South Korea Blood Disorder Market
The South Korea blood disorder market is analyzed through a combination of primary and secondary research methodologies to ensure accurate market intelligence and forecasting. Primary research includes interviews with hematologists, hospitals, diagnostic laboratories, pharmaceutical companies, and healthcare experts. Secondary research involves company reports, government healthcare databases, scientific publications, clinical studies, and industry journals. Market sizing, trend analysis, forecasting models, and investment assessments are utilized to evaluate future opportunities and competitive developments.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Blood Disorder Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Blood Disorder Market
• Roche Holding AG
• Novartis AG
• Pfizer Inc.
• Johnson & Johnson
• Bristol Myers Squibb
• Takeda Pharmaceutical Company
• Sanofi
• CSL Behring
• Amgen Inc.
• Korea Green Cross Corporation
Recent Developments:
- In February 2026, Novartis AG expanded its hematology portfolio with advanced therapies targeting rare blood disorders and hematologic cancers.
- In August 2025, Pfizer Inc. announced progress in clinical research programs focused on innovative treatments for hemophilia and inherited blood disorders.
Market Segmentation:
South Korea Blood Disorder Market, By Disorder Type
• Anemia
• Hemophilia
• Leukemia
• Thalassemia
• Sickle Cell Disease
South Korea Blood Disorder Market, By Treatment Type
• Pharmaceuticals
• Biologics
• Blood Transfusion Services
• Gene Therapy
• Stem Cell Therapy
South Korea Blood Disorder Market, By End User
• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Research Institutes
• Blood Banks
Expert Views:
The growth of the South Korea blood disorder market will be driven by increasing prevalence of hematologic diseases, expanding access to advanced diagnostics, and rising adoption of precision medicine. Integration of gene therapies, biologics, and AI-assisted diagnostic platforms will improve treatment outcomes and disease management. Growing investments in hematology research, rare disease therapies, and healthcare infrastructure will further strengthen market expansion through 2035.
Author: Govind and Krishna By Decisions Advisors and Consulting